Shamburg News · 8-K filed Nov 12, 2026, 7:16 AM EST
Generate Biomedicines Reports Q3 2026 Results; Net Loss Widens to $87.7 Million
GENB · Generate Biomedicines, Inc.
- Earnings
- Materiality: high
Generate Biomedicines reported third quarter 2026 results for the quarter ended September 30, 2026, with collaboration revenue of $4.2 million, down from $9.6 million a year earlier. Research and development expenses were $82.3 million and net loss was $87.7 million, or $0.68 per share, compared with a net loss of $60.0 million in the prior-year quarter. Cash, cash equivalents, and marketable securities were $404.2 million as of September 30, 2026.
Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001193125-26-456921.
Written from the filing by Shamburg Markets. Figures are as reported by the company.